Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 10581.145 | 0.1401 | -0.7723 | 0.9044 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.000256 | uM | 11854.145 | 0.8704 | 0.7741 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.00128 | uM | 11854.145 | 0.8957 | 0.8185 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.0064 | uM | 11854.145 | 0.9824 | 0.9695 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.032 | uM | 11854.145 | 0.9962 | 0.9935 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.16 | uM | 11854.145 | 1.0538 | 1.0925 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 0.8 | uM | 11854.145 | 0.8776 | 0.7867 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 4 | uM | 11854.145 | 0.3967 | -0.1000 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 20 | uM | 11854.145 | 0.1028 | -0.7195 | 1.1581 | |
| BT-20 | TNBC | Basal A | Bosutinib | Src | nRTK | 100 | uM | 11854.145 | 0.1513 | -0.6084 | 1.1581 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 12056.145 | 0.8782 | 0.7124 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 12056.145 | 0.8692 | 0.6913 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 12056.145 | 0.9010 | 0.7656 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 12056.145 | 0.9659 | 0.9186 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 12056.145 | 0.9613 | 0.9078 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 12056.145 | 0.8123 | 0.5599 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 4 | uM | 12056.145 | 0.6417 | 0.1768 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 20 | uM | 12056.145 | 0.1841 | -0.7356 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 100 | uM | 12056.145 | 0.3140 | -0.4993 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 12178.145 | 0.9383 | 0.8025 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 12178.145 | 0.9757 | 0.9212 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 12178.145 | 0.9268 | 0.7667 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 12178.145 | 0.9739 | 0.9154 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 12178.145 | 0.9877 | 0.9601 | 0.6127 | |
| BT-474 | HER2amp | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 12178.145 | 0.8975 | 0.6763 | 0.6127 |